Marksans Pharma Announces Audited Financial Results and Recommends Final Dividend for FY 2025-26
Marksans Pharma Limited released its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, on May 26, 2026. The company also announced that its Board of Directors recommended a final dividend for the financial year 2025-26.The Board's recommendation detailed a final dividend of Rs. 70.90 per equity share of face value of 71/- each (90%) for the Financial Year 2025-26. The dividend will be credited or dispatched within 30 days from the date of the forthcoming Annual General Meeting (AGM).
Financial Performance Overview
The detailed audited financial statements reflect the Group's activities in the pharmaceutical sector. The Standalone Statement of Financial Results and the Consolidated Statement of Financial Results for the year ended March 31, 2026, were presented alongside the respective audited balance sheets and cash flow statements.Standalone Financial Highlights (Year Ended March 31, 2026)
The standalone results show the following key performance indicators for the year ended March 31, 2026, compared to the year ended March 31, 2025:| Metric | 31 Mar 2026 (Audited) | 31 Mar 2025 (Audited) |
|---|---|---|
| Total Income | 14,450.09 (₹ in million) | 12,401.61 (₹ in million) |
| Total Expenses | 2,171.48 (₹ in million) | 2,246.62 (₹ in million) |
| Profit Before Tax | 10,534.66 (₹ in million) | 9,969.02 (₹ in million) |
| Profit After Tax | 908.45 (₹ in million) | 549.87 (₹ in million) |
| Total Comprehensive Income | 10,413.01 (₹ in million) | 3,017.39 (₹ in million) |
| Basic Earnings Per Share | 6.64 | 4.15 |
***
Consolidated Financial Highlights (Year Ended March 31, 2026)
The consolidated results, which include subsidiaries such as Marksans Pharma (UK) Limited, Marksans Pharma Inc., and Marksans Pharma (Europe) Limited, show a robust year-on-year growth:| Metric | 31 Mar 2026 (Audited) | 31 Mar 2025 (Audited) |
|---|---|---|
| Total Income | 30,334.71 (₹ in million) | 26,891.74 (₹ in million) |
| Total Expenses | 6,519.46 (₹ in million) | 5,961.20 (₹ in million) |
| Profit Before Tax | 24,729.16 (₹ in million) | 21,852.07 (₹ in million) |
| Profit After Tax | 1,404.91 (₹ in million) | 1,213.48 (₹ in million) |
| Total Comprehensive Income | 1,761.48 (₹ in million) | 483.48 (₹ in million) |
| Basic Earnings Per Share | 9.22 | 8.40 |
Balance Sheet Status
The balance sheets reveal significant increases in total asset size. The total assets for the Group stood at 27,227.40 million on March 31, 2026, compared to 22,041.21 million on the previous year. Total equity and liabilities reached 38,609.02 million, up from 32,396.32 million a year prior.Cash Flow Generation
The company generated substantial net cash from operating activities. Consolidated cash flow from operations was 4,581.25 million for the year ended March 31, 2026, improving from 2,066.64 million in the previous year.For a detailed review of the financial results, including the full audited balance sheet, cash flow statement, and supporting notes, interested parties can visit the company website, www.marksanspharma.com, and the respective stock exchange websites.
MARKSANS Stock Price Movement
Marksans Pharma Limited shares are rallying to ₹248.31 as of 2:50 PM, climbing 12.73% in live trading. The stock is experiencing heavy participation, with over 28.84 million shares trading during the active session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: